Stathmin is upregulated in many solid cancers, including endometrial cancer [1], [6]–[14], and its upregulation has been associated with clinicopathological variables of aggressive disease such as increased risk of lymph node metastasis [9], [15] and poor survival [6], [9], [10], [12], [13], [16], confirming stathmins role as a prognostic biomarker. Here, STMN1 is linked to endometrial cancer.